Current Developments in Pharmacogenomics of Multiple Sclerosis

被引：5
|
作者：
Carlson, Rebecca J. [1 ,2 ]
Doucette, J. Ronald [2 ,3 ,4 ]
Nazarali, Adil J. [1 ,4 ,5 ]
机构：
[1] Univ Saskatchewan, Coll Pharm & Nutr, Mol Cell Biol Lab, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5C9, Canada
[3] Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5C9, Canada
[4] City Hosp, Cameco Multiple Sclerosis Neurosci Res Ctr, Saskatoon, SK, Canada
[5] Univ Saskatchewan, Neurosci Res Grp, Saskatoon, SK S7N 5E2, Canada
来源：
CELLULAR AND MOLECULAR NEUROBIOLOGY | 2014年 / 34卷 / 08期
基金：
加拿大健康研究院;
关键词：
Pharmacogenomics; Multiple sclerosis; Interferon-beta; Glatiramer acetate; SNPs; Genome-wide association studies; INTERFERON-BETA THERAPY; GLATIRAMER ACETATE; GENE; SUSCEPTIBILITY; POLYMORPHISMS; MARKERS;
D O I：
10.1007/s10571-014-0095-0
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Pharmacogenomics has a significant potential to impact how we treat diseases. It involves targeting genetically identifiable populations with therapeutic interventions that promises to yield immediate positive health outcomes with lower or no side effects. The 'trial and error' method of treatment will no longer be necessary with the successful implementation of personalized medicine. The following is an overview of some new developments in pharmacogenomics of multiple sclerosis, and how it has the potential to improve future treatment.
引用
收藏
页码：1081 / 1085
页数：5
相关论文
共 50 条
  • [31] Current developments in MRI for assessing rodent models of multiple sclerosis
    Alomair, Othman I.
    Smith, Maree T.
    Brereton, Ian M.
    Galloway, Graham J.
    Kurniawan, Nyoman D.
    FUTURE NEUROLOGY, 2014, 9 (04) : 487 - 511
  • [32] Personalized Treatment in Multiple Sclerosis
    Correale, Jorge
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2011, 11 (06) : 523 - 525
  • [33] Personalized Treatment in Multiple Sclerosis
    Jorge Correale
    Current Neurology and Neuroscience Reports, 2011, 11 : 523 - 525
  • [34] Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients
    Kulakova, Olga G.
    Tsareva, Ekaterina Yu
    Boyko, Alexey N.
    Shchur, Sergey G.
    Gusev, Evgeny I.
    Lvovs, Dmitrijs
    Favorov, Alexander V.
    Vandenbroeck, Koen
    Favorova, Olga O.
    PHARMACOGENOMICS, 2012, 13 (15) : 1689 - 1700
  • [35] Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
    Wiendl, H.
    Toyka, K. V.
    Rieckmann, P.
    Gold, R.
    Hartung, H. -P.
    Hohlfeld, R.
    JOURNAL OF NEUROLOGY, 2008, 255 (10) : 1449 - 1463
  • [36] Current evidence and therapeutic strategies for multiple sclerosis
    Wingerchuk, Dean M.
    SEMINARS IN NEUROLOGY, 2008, 28 (01) : 56 - 68
  • [37] The current role of mitoxantrone in the treatment of multiple sclerosis
    Cocco, Eleonora
    Marrosu, Maria Giovanna
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (06) : 607 - 616
  • [38] Current Therapeutic Options in Pediatric Multiple Sclerosis
    E. Ann Yeh
    Current Treatment Options in Neurology, 2011, 13 : 544 - 559
  • [39] Multiple Sclerosis
    Kim, Woojun
    Kim, Ho Jin
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2009, 52 (07): : 665 - 676
  • [40] Pharmacogenomics of IFN-β in multiple sclerosis: towards a personalized medicine approach
    Vosslamber, Saskia
    van Baarsen, Lisa G. M.
    Verweij, Cornelis L.
    PHARMACOGENOMICS, 2009, 10 (01) : 97 - 108
12345